Influence-Tools/republic-os
2
0
Fork 0
Code Issues Pull Requests Actions Packages Projects Releases Wiki Activity
Files
5a13be122b7664b816795febdadddffadd13d862
republic-os/legislation/us/states/co/2021a/sb-21-175.md
T
Fabio a43f31b272 Legislation: batch A — AK AL AR AZ CO CT DE GA HI IA ID 
Co-Authored-By: Claude Opus 4.8 <noreply@anthropic.com>
2026-07-06 17:26:56 -04:00

9.3 KiB
Raw Blame History

type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags
type title description jurisdiction legislature session identifier citation classification subjects status primary_sponsors version_count action_count vote_count first_action last_action source source_identifier source_url source_hash vintage source_snapshot retrieved_at confidence tags
Bill Prescription Drug Affordability Review Board The act creates the Colorado prescription drug affordability review board (board) in the division of insurance (division) in the department of regulatory agencies as an independent unit of state government, requires the board to perform affordability reviews of prescription drugs, and authorizes the board to establish upper payment limits for prescription drugs the board determines are unaffordable for Colorado consumers. The board is also required to promulgate rules as necessary for its purposes.The board shall determine by rule the methodology for establishing an upper payment limit for a prescription drug. An upper payment limit applies to all purchases of and payer reimbursements for the prescription drug dispensed or administered to individuals in the state in person, by mail, or by other means. Any savings generated for a health benefit plan as a result of an upper payment limit established by the board must be used by the carrier that issued the health benefit plan to reduce costs to consumers, prioritizing the reduction of out-of-pocket costs for prescription drugs.On and after January 1, 2022, the act prohibits, with certain exceptions, any purchase or payer reimbursement for a prescription drug at an amount that exceeds the upper payment limit established by the board for that prescription drug.A person aggrieved by a decision of the board may appeal the decision within 60 days. The board shall consider the appeal and issue a final decision concerning the appeal within 60 days after the board receives the appeal. Final board decisions are subject to judicial review.Any prescription drug manufacturer (manufacturer) that intends to withdraw from sale or distribution within the state a prescription drug for which the board has established an upper payment limit must notify, at least 180 days before the withdrawal:The commissioner; us/states/co Colorado General Assembly 2021A SB 21-175 Colorado SB 21-175 (2021A)
bill
enacted
Chris Kennedy
Julie Gonzales
Sonya Jaquez Lewis
Yadira Caraveo
11 20 12 2021-03-08T07:00:00+00:00 2021-06-16T06:00:00+00:00 openstates ocd-bill/5a89613a-7914-4b19-a0b7-b071d588a307 http://leg.colorado.gov/bills/sb21-175 d20a3359a1418c4a73f055cea2680f953482d4474ce3dd3f73a26708244b1823 2026-07-01 https://data.openstates.org/daily/2026-07-01/public.pgdump 2026-07-06 reported
legislation
bill
us-co

Colorado SB 21-175 (2021A) — Prescription Drug Affordability Review Board

The act creates the Colorado prescription drug affordability review board (board) in the division of insurance (division) in the department of regulatory agencies as an independent unit of state government, requires the board to perform affordability reviews of prescription drugs, and authorizes the board to establish upper payment limits for prescription drugs the board determines are unaffordable for Colorado consumers. The board is also required to promulgate rules as necessary for its purposes.The board shall determine by rule the methodology for establishing an upper payment limit for a prescription drug. An upper payment limit applies to all purchases of and payer reimbursements for the prescription drug dispensed or administered to individuals in the state in person, by mail, or by other means. Any savings generated for a health benefit plan as a result of an upper payment limit established by the board must be used by the carrier that issued the health benefit plan to reduce costs to consumers, prioritizing the reduction of out-of-pocket costs for prescription drugs.On and after January 1, 2022, the act prohibits, with certain exceptions, any purchase or payer reimbursement for a prescription drug at an amount that exceeds the upper payment limit established by the board for that prescription drug.A person aggrieved by a decision of the board may appeal the decision within 60 days. The board shall consider the appeal and issue a final decision concerning the appeal within 60 days after the board receives the appeal. Final board decisions are subject to judicial review.Any prescription drug manufacturer (manufacturer) that intends to withdraw from sale or distribution within the state a prescription drug for which the board has established an upper payment limit must notify, at least 180 days before the withdrawal:The commissioner;

Version chain

The bill's text revisions, in order — the diff chain from filing to enrollment.

  1. Committee Amendment (committee substitute) — source
  2. Engrossed (05/06/2021) (committee substitute) — source
  3. Final Act (06/15/2021) (committee substitute) — source
  4. Introduced (03/08/2021) (committee substitute) — source
  5. PA1 (03/18/2021) (committee substitute) — source
  6. PA2 (04/30/2021) (committee substitute) — source
  7. PA3 (05/25/2021) (committee substitute) — source
  8. Reengrossed (05/07/2021) (committee substitute) — source
  9. Rerevised (06/07/2021) (committee substitute) — source
  10. Revised (06/04/2021) (committee substitute) — source
  11. Signed Act (06/16/2021) (committee substitute) — source

Votes

  • REPASS — 18–16 (pass) · upper
  • AMD — 23–39 (fail) · lower
  • permission for 3rd — 17–18 (fail) · upper
  • BILL — 19–16 (pass) · upper
  • COW * — 17–17 (fail) · upper
  • COW * — 20–14 (pass) · upper
  • REPASS — 19–15 (pass) · upper
  • AMD — 23–39 (fail) · lower
  • AMD — 23–39 (fail) · lower
  • CONCUR — 34–0 (pass) · upper
  • BILL — 41–22 (pass) · lower
  • AMD — 24–38 (fail) · lower

Sponsors

  • Chris Kennedy — primary (person)
  • Julie Gonzales — primary (person)
  • Sonya Jaquez Lewis — primary (person)
  • Yadira Caraveo — primary (person)

Timeline

The legislative action history — every referral, reading, and vote.

  • 2021-06-16T06:00:00+00:00 Governor Signed executive-signature
  • 2021-06-15T06:00:00+00:00 Sent to the Governor executive-receipt
  • 2021-06-15T06:00:00+00:00 Signed by the Speaker of the House
  • 2021-06-15T06:00:00+00:00 Signed by the President of the Senate
  • 2021-06-08T06:00:00+00:00 Senate Considered House Amendments - Result was to Pass
  • 2021-06-08T06:00:00+00:00 Senate Considered House Amendments - Result was to Reconsider
  • 2021-06-08T06:00:00+00:00 Senate Considered House Amendments - Result was to Concur - Repass
  • 2021-06-07T06:00:00+00:00 House Third Reading Passed - No Amendments passage, reading-3
  • 2021-06-04T06:00:00+00:00 House Second Reading Special Order - Passed with Amendments - Committee, Floor
  • 2021-06-03T06:00:00+00:00 House Second Reading Special Order - Laid Over Daily - No Amendments
  • 2021-05-27T06:00:00+00:00 House Second Reading Laid Over Daily - No Amendments
  • 2021-05-25T06:00:00+00:00 House Committee on Appropriations Refer Amended to House Committee of the Whole committee-passage, referral-committee
  • 2021-05-19T06:00:00+00:00 House Committee on Health & Insurance Refer Unamended to Appropriations referral-committee
  • 2021-05-11T06:00:00+00:00 Introduced In House - Assigned to Health & Insurance introduction
  • 2021-05-07T06:00:00+00:00 Senate Third Reading Passed - No Amendments passage, reading-3
  • 2021-05-06T06:00:00+00:00 Senate Second Reading Passed with Amendments - Committee, Floor reading-2
  • 2021-05-04T06:00:00+00:00 Senate Second Reading Laid Over Daily - No Amendments
  • 2021-04-30T06:00:00+00:00 Senate Committee on Appropriations Refer Amended to Senate Committee of the Whole committee-passage, referral-committee
  • 2021-03-17T06:00:00+00:00 Senate Committee on Health & Human Services Refer Amended to Appropriations referral-committee
  • 2021-03-08T07:00:00+00:00 Introduced In Senate - Assigned to Health & Human Services introduction

Source

OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/5a89613a-7914-4b19-a0b7-b071d588a307. Confidence: reported (aggregated from official Colorado legislature records).

Reference in New Issue View Git Blame Copy Permalink